60 Degrees Pharmaceuticals’ (SXTP) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research note issued to investors on Monday,Benzinga reports.

60 Degrees Pharmaceuticals Stock Performance

NASDAQ:SXTP opened at $1.16 on Monday. The stock has a market cap of $2.66 million, a price-to-earnings ratio of -0.12 and a beta of 5.36. 60 Degrees Pharmaceuticals has a 1 year low of $0.70 and a 1 year high of $18.36. The business has a fifty day moving average of $1.09 and a 200-day moving average of $0.90.

Insider Buying and Selling at 60 Degrees Pharmaceuticals

In other news, CEO Geoffrey S. Dow purchased 35,823 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was purchased at an average cost of $1.27 per share, with a total value of $45,495.21. Following the purchase, the chief executive officer now owns 94,580 shares in the company, valued at $120,116.60. This trade represents a 60.97 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have purchased 66,372 shares of company stock valued at $82,410. Company insiders own 10.27% of the company’s stock.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.